Investing in Amicus Therapeutics, Inc. (FOLD)  ➔  Intrinsic value

Prev. close$10.25 
ModelValueUpside
Chepakovich$0.41-96%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$10.25  
Valuation MethodValuePotential 
Chepakovich Model$0.41-96%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.